Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. (Nasdaq: ESLA) is a clinical-stage biopharmaceutical company operating in the oncology and immunotherapy sector. The company went public through a SPAC business combination and filed an 8-K current report with the SEC on October 5, 2023, under accession number 0001013762-23-002216. As a post-merger entity, Estrella is focused on developing novel immunotherapeutic candidates targeting cancer, placing it within the broader healthcare and life sciences segment that has attracted significant SPAC activity in recent years. The company remains in the clinical development stage as of its most recent filings. For complete filing history, deal terms, shareholder data, and real-time alerts on ESLA and hundreds of other SPAC-related entities, sign up for full access at SpacDesk.